Ultime notizie per Orgenesis (OTC:ORGS) Azioni

Orgenesis

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Earnings

Press Releases

Orgenesis Provides Second Quarter 2024 Business Update

General

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Health Care

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis Announces Reverse Stock Split

Markets

Orgenesis Commences Trading on OTCQX® Best Market

Orgenesis Provides Third Quarter 2024 Business Update

Offerings

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

ORGS

Benchmark

Comments

Orgenesis

Notizie

Ultime notizie per Orgenesis (OTC:ORGS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO